Targeting ferroptosis, the achilles’ heel of breast cancer: A review

Liu, Yang; Hu, Yanrong; Yi, Jing; Bu, Jiawen; Gu, Xianfeng

doi:10.3389/fphar.2022.1036140

Cited by 13 publications

(8 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, it is interesting to note that the ferroptosis pathway is largely represented. This type of cell death is increasingly studied in the context of cancer [245] in line with non-coding RNAs [246], as well as recently-in particular-in the ER-/AR+ BC subtype [247]. Our analysis reflects the complexity of miRNA interactions in TNBC carcinogenesis, i.e., where the existence of a set of signaling pathways that are reported to be implicated in TNBC hostility is indicated.…”

Section: Mirna Implications In Breast Cancermentioning

confidence: 93%

See 1 more Smart Citation

ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!

Chamandi,

El-Hajjar,

El Kurdi

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Breast cancer (BC), the most prevalent cancer in women, is a heterogenous disease. Despite advancements in BC diagnosis, prognosis, and therapeutics, survival rates have drastically decreased in the metastatic setting. Therefore, BC still remains a medical challenge. The evolution of high-throughput technology has highlighted gaps in the classification system of BCs. Of particular interest is the notorious triple negative BC, which was recounted as being heterogenous itself and it overlaps with distinct subtypes, namely molecular apocrine (MA) and luminal androgen (LAR) BCs. These subtypes are, even today, still misdiagnosed and poorly treated. As such, researchers and clinicians have been looking for ways through which to refine BC classification in order to properly understand the initiation, development, progression, and the responses to the treatment of BCs. One tool is biomarkers and, specifically, microRNA (miRNA), which are highly reported as associated with BC carcinogenesis. In this review, the diverse roles of miRNA in estrogen receptor negative (ER−) and androgen receptor positive (AR+) BC are depicted. While highlighting their oncogenic and tumor suppressor functions in tumor progression, we will discuss their diagnostic, prognostic, and predictive biomarker potentials, as well as their drug sensitivity/resistance activity. The association of several miRNAs in the KEGG-reported pathways that are related to ER-BC carcinogenesis is presented. The identification and verification of accurate miRNA panels is a cornerstone for tackling BC classification setbacks, as is also the deciphering of the carcinogenesis regulators of ER − AR + BC.

show abstract

Section: Mirna Implications In Breast Cancermentioning

confidence: 93%

Section: Mirna Implications In Breast Cancermentioning

confidence: 99%

ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!

Chamandi,

El-Hajjar,

El Kurdi

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…[8] Currently, a single treatment can hardly fulfill the therapeutic needs of BRCA. Emerging evidences suggest that features based on cell death patterns, such as ferroptosis, [9] pyroptosis, [10] and necroptosis, [11] have significant value in predicting the prognosis, tumor immune microenvironment, and immune therapy response of BRCA patients. Researchers established a cell death index model by comprehensively analyzing diverse cell death patterns, which can accurately predict clinical prognosis and drug sensitivity of triple negative breast cancer (TNBC) after surgery.…”

Section: Introductionmentioning

confidence: 99%

A novel cuproptosis-related genes model in breast cancer prognosis

Zheng¹,

Shi²,

Zhang

et al. 2023

Medicine

View full text Add to dashboard Cite

Breast cancer (BRCA) is a highly heterogeneous malignancy with an urgent need to build a proper model to predict its prognosis. Cuproptosis is a recently discovered form of cell death, mediated by protein fatty acylation and tightly associated with mitochondrial metabolism. The role of cuproptosis-related genes (CRGs) in BRCA remains to be explored. We aimed to investigate the applications of CRGs in BRCA prognosis in different clinical contexts, including chemotherapy and immunotherapy, via bioinformatics analysis of the messenger RNA profiles and clinical data obtained from public databases. Molecular subtyping of CRGs was performed through consistent clustering analysis. Differentially expressed genes between different CRG clusters were identified. The differentially expressed genes were then used to build a risk assessment model using least absolute shrinkage and selection operator regression to predict patient survival with BRCA. The model was then validated with the data from the Molecular Taxonomy of Breast Cancer International Consortium, GSE96058, and GSE20685. Differences in somatic mutations, copy number variations, hallmark pathways, drug responses, and prognosis of immunotherapy and chemotherapy were analyzed by comparing the high-risk and low-risk groups. Patients with high-risk scores showed worse overall survival than those with low-risk scores. The results indicated significant differences between the 2 groups immune-related biological pathways and the variable immune status. It also suggests the differential sensitivity to chemotherapy between the 2 groups. The CRGs model showed the promise to predict the prognosis of BRCA patients and shed light on their treatment.

show abstract

“…Numerous studies have demonstrated the involvement of ferroptosis in breast cancer tumorigenesis, progression, invasion and drug resistance 23,24 . Inducing ferroptosis in breast cancer cells can effectively inhibit tumour growth, promising the development of novel anti‐breast cancer drugs and overcoming drug resistance 25 . Furthermore, natural products serve as vital resources for identifying lead compounds in anti‐breast cancer drug discovery 26,27 .…”

Section: Introductionmentioning

confidence: 99%

“… 23 , 24 Inducing ferroptosis in breast cancer cells can effectively inhibit tumour growth, promising the development of novel anti‐breast cancer drugs and overcoming drug resistance. 25 Furthermore, natural products serve as vital resources for identifying lead compounds in anti‐breast cancer drug discovery. 26 , 27 Recent investigations have revealed that several natural medicinal compounds regulate ferroptosis in breast cancer cells, exhibiting anti‐breast cancer effects.…”

Section: Introductionmentioning

confidence: 99%

Mechanism of ferroptosis in breast cancer and research progress of natural compounds regulating ferroptosis

Ge,

He,

Zhao

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Breast cancer is the most prevalent cancer worldwide and its incidence increases with age, posing a significant threat to women's health globally. Due to the clinical heterogeneity of breast cancer, the majority of patients develop drug resistance and metastasis following treatment. Ferroptosis, a form of programmed cell death dependent on iron, is characterized by the accumulation of lipid peroxides, elevated levels of iron ions and lipid peroxidation. The underlying mechanisms and signalling pathways associated with ferroptosis are intricate and interconnected, involving various proteins and enzymes such as the cystine/glutamate antiporter, glutathione peroxidase 4, ferroptosis inhibitor 1 and dihydroorotate dehydrogenase. Consequently, emerging research suggests that ferroptosis may offer a novel target for breast cancer treatment; however, the mechanisms of ferroptosis in breast cancer urgently require resolution. Additionally, certain natural compounds have been reported to induce ferroptosis, thereby interfering with breast cancer. Therefore, this review not only discusses the molecular mechanisms of multiple signalling pathways that mediate ferroptosis in breast cancer (including metastasis, invasion and proliferation) but also elaborates on the mechanisms by which natural compounds induce ferroptosis in breast cancer. Furthermore, this review summarizes potential compound types that may serve as ferroptosis inducers in future tumour cells, providing lead compounds for the development of ferroptosis‐inducing agents. Last, this review proposes the potential synergy of combining natural compounds with traditional breast cancer drugs in the treatment of breast cancer, thereby suggesting future directions and offering new insights.

show abstract

Targeting ferroptosis, the achilles’ heel of breast cancer: A review

Cited by 13 publications

References 115 publications

ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!

ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!

A novel cuproptosis-related genes model in breast cancer prognosis

Mechanism of ferroptosis in breast cancer and research progress of natural compounds regulating ferroptosis

Contact Info

Product

Resources

About